Compare
Two to four companies, one screen
The same numbers the feed and each dossier publish, lined up so you can weigh candidates against each other. Every figure is a public-filing estimate, identical for every subscriber, and the shaded cell in a row is simply the highest number in it — not a recommendation.
Add one more to line them up.
| Regeneron Pharmaceuticals OncologyPhase III Remove | |
|---|---|
| Momentum0–100 | 100 |
| Runwayestimate, months | — |
| Stage | Phase III |
| Last raiseForm D, self-reported | No Form D on file |
| Lead investigator | — |
| What changed | Phase I trial registered: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments1w ago · Trial registered |
| Full dossier → |
Momentum and runway are estimates derived from public federal filings, published identically to every subscriber. This is informational only and is not investment advice. How the numbers work